Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Mineralys Therapeutics, Inc. Common Stock

Healthcare US MLYS

25.06USD
-3.79(13.14%)

Last update at 2026-06-03T20:07:00Z

Day Range

23.6426.78
LowHigh

52 Week Range

5.8517.44
LowHigh

Fundamentals

  • Previous Close 28.85
  • Market Cap597.27M
  • Volume8172064
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -29.79900M -19.40800M -3.42600M
Minority interest - - -
Net income -29.79900M -19.40800M -3.42600M
Selling general administrative 5.23M 2.42M 0.53M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation - - -
Ebit -31.47900M -18.72500M -2.94300M
Ebitda -31.47900M -18.72400M -2.94400M
Depreciation and amortization - 0.00100M -0.00100M
Non operating income net other - - -
Operating income -31.47900M -18.72500M -2.94300M
Other operating expenses 31.48M 18.73M 2.94M
Interest expense - 0.03M 0.12M
Tax provision - - -
Interest income 1.68M - -
Net interest income 1.68M -0.02700M -0.11500M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - 0.03M 0.12M
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 31.48M 18.73M 2.94M
Cost of revenue - - -
Total other income expense net 0.00400M -0.65600M -0.36800M
Discontinued operations - - -
Net income from continuing ops -29.79900M -19.40800M -3.42600M
Net income applicable to common shares -29.79900M -19.40800M -3.42600M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 251.64M 114.44M 11.12M 1.49M
Intangible assets - - - -
Earning assets - - - -
Other current assets 12.54M 2.70M 0.51M 0.06M
Total liab 10.48M 166.71M 34.05M 5.08M
Total stockholder equity 241.15M -52.26900M -22.92500M -3.59700M
Deferred long term liab - 1.63M 0.00300M -
Other current liab 9.88M 6.16M 4.29M 0.05M
Common stock 0.00400M 0.00100M 0.00100M 0.00100M
Capital stock 0.00400M 0.00100M 0.00100M 0.00100M
Retained earnings -124.70800M -52.81000M -23.01100M -3.60300M
Other liab - - - -
Good will - - - -
Other assets 0.00000M 1.63M 0.00300M 0.02M
Cash 49.30M 87.70M 10.61M 1.41M
Cash and equivalents - - - -
Total current liabilities 10.48M 8.07M 5.05M 5.08M
Current deferred revenue - - - -
Net debt -49.30400M -87.70100M -10.61200M 3.09M
Short term debt - - - 4.50M
Short long term debt - - - 4.50M
Short long term debt total - - - 4.50M
Other stockholder equity 365.86M 0.54M -28.91100M 0.00500M
Property plant equipment - - - -
Total current assets 249.10M 110.11M 11.12M 1.47M
Long term investments 2.48M - - -
Net tangible assets - -52.26900M -22.92500M -3.59700M
Short term investments 187.26M 22.41M - -
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 0.60M 1.91M 0.76M 0.53M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -251.63600M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.05M - - -
Deferred long term asset charges - - - -
Non current assets total 2.53M 4.33M 0.00300M 0.02M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -21.75900M -21.75900M -21.75900M
Change to liabilities 3.01M 4.47M 0.54M
Total cashflows from investing activities -21.75900M -21.75900M -21.75900M
Net borrowings - - 3.85M
Total cash from financing activities 128.02M 23.81M 3.83M
Change to operating activities -2.24000M -0.38600M -0.05700M
Net income -29.79900M -19.40800M -3.42600M
Change in cash 77.04M 9.25M 1.37M
Begin period cash flow 10.66M 1.41M 0.04M
End period cash flow 87.70M 10.66M 1.41M
Total cash from operating activities -29.22100M -14.55900M -2.46300M
Issuance of capital stock 129.65M 23.81M -
Depreciation - - -
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -0.02000M
Other cashflows from financing activities 128.02M -1.62900M 3.85M
Change to netincome -0.19400M 0.76M 0.48M
Capital expenditures 0.00000M 0.00000M 0.00000M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.77M 4.08M 0.48M
Stock based compensation 0.46M 0.08M 0.00100M
Other non cash items -0.64900M 0.68M 0.48M
Free cash flow -29.22100M -14.55900M -2.46300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MLYS
Mineralys Therapeutics, Inc. Common Stock		 -3.79 13.14% 25.06 - - - 2.67 -7.6462
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc. Common Stock

150 N. Radnor Chester Rd., Radnor, PA, United States, 19087

Key Executives

Name Title Year Born
Mr. Jon Congleton CEO & Director 1963
Mr. Adam Scott Levy CFO & Secretary 1978
Dr. David M. Rodman M.D. Chief Medical Officer 1955
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. Founder & Executive Chairman 1977
Ms. Cindy Berejikian Executive Vice President of Operations NA
Ms. Sarah Foster Vice President of Human Resources NA
Dr. Robert McKean Ph.D. Senior Vice President of CMC NA
Ms. Danielle Bradbury Senior Vice President of Quality Assurance NA
Mr. Jeffrey N. Fellows Senior Vice President of Regulatory Affairs NA
Ms. Jessica Ibbitson Senior Vice President of Clinical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions